Literature DB >> 23240984

Selective carbohydrate utilization by lactobacilli and bifidobacteria.

D Watson1, M O'Connell Motherway, M H C Schoterman, R J Joost van Neerven, A Nauta, D van Sinderen.   

Abstract

AIM: To evaluate the ability of specific carbohydrates, including commercially available products, to support the growth of representatives of two well-known groups of gut commensals, namely lactobacilli and bifidobacteria. METHODS AND
RESULTS: Sixty-eight bacterial strains, representing 29 human-derived lactobacilli and 39 bifidobacteria (both human- and animal-derived), were tested for their ability to metabolize 10 different carbohydrates. Analysis of growth and metabolic activity was performed using a combination of diagnostic parameters, such as final OD600 , final pH, fermentation end products and growth rate.
CONCLUSIONS: The data assembled in this study provide significant complementary and comparative information on the growth-promoting properties of a range of carbohydrates, while also investigating interspecies differences between lactobacilli and/or bifidobacteria with regard to their carbohydrate utilization abilities. Galacto-oligosaccharides (GOS) and lactulose were shown to support the most favourable growth characteristics, whereas relatively poor growth of lactobacilli and bifidobacteria was observed on inulin, maltodextrin and polydextrose. GOS/inulin (9 : 1) and fructo-oligosaccharides (FOS)/inulin mixtures supported mostly similar growth abilities to those obtained for GOS and FOS, respectively. Microbial consumption of GOS, as determined by high-performance anion-exchange chromatography with pulsed amperometric detection, was evident for both lactobacilli and bifidobacteria. SIGNIFICANCE AND IMPACT OF THE STUDY: These results may allow for the rational prediction of lactobacilli and/or bifidobacteria to be used in conjunction with prebiotics, such as GOS, as synbiotics.
© 2012 University College Cork © 2012 The Society for Applied Microbiology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23240984     DOI: 10.1111/jam.12105

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  55 in total

Review 1.  The role of the gut microbiome in systemic inflammatory disease.

Authors:  Jose C Clemente; Julia Manasson; Jose U Scher
Journal:  BMJ       Date:  2018-01-08

Review 2.  Probiotics, Prebiotics, and Synbiotics for the Prevention of Necrotizing Enterocolitis.

Authors:  Kathene C Johnson-Henry; Thomas R Abrahamsson; Richard You Wu; Philip M Sherman
Journal:  Adv Nutr       Date:  2016-09-15       Impact factor: 8.701

Review 3.  Engineering the Microbiome: a Novel Approach to Immunotherapy for Allergic and Immune Diseases.

Authors:  Nan Shen; Jose C Clemente
Journal:  Curr Allergy Asthma Rep       Date:  2015-07       Impact factor: 4.806

4.  A Human Gut Commensal Ferments Cranberry Carbohydrates To Produce Formate.

Authors:  Ezgi Özcan; Jiadong Sun; David C Rowley; David A Sela
Journal:  Appl Environ Microbiol       Date:  2017-08-17       Impact factor: 4.792

Review 5.  Infant food applications of complex carbohydrates: Structure, synthesis, and function.

Authors:  Dorothy L Ackerman; Kelly M Craft; Steven D Townsend
Journal:  Carbohydr Res       Date:  2016-11-11       Impact factor: 2.104

6.  Bifidobacterium breve UCC2003 Employs Multiple Transcriptional Regulators To Control Metabolism of Particular Human Milk Oligosaccharides.

Authors:  Kieran James; Mary O'Connell Motherway; Christophe Penno; Rebecca Louise O'Brien; Douwe van Sinderen
Journal:  Appl Environ Microbiol       Date:  2018-04-16       Impact factor: 4.792

7.  Complementary Mechanisms for Degradation of Inulin-Type Fructans and Arabinoxylan Oligosaccharides among Bifidobacterial Strains Suggest Bacterial Cooperation.

Authors:  Audrey Rivière; Marija Selak; Annelies Geirnaert; Pieter Van den Abbeele; Luc De Vuyst
Journal:  Appl Environ Microbiol       Date:  2018-04-16       Impact factor: 4.792

8.  Metabolism of sialic acid by Bifidobacterium breve UCC2003.

Authors:  Muireann Egan; Mary O'Connell Motherway; Marco Ventura; Douwe van Sinderen
Journal:  Appl Environ Microbiol       Date:  2014-05-09       Impact factor: 4.792

Review 9.  Lactoferrin for prevention of neonatal sepsis.

Authors:  Christie G Turin; Alonso Zea-Vera; Alonso Pezo; Karen Cruz; Jaime Zegarra; Sicilia Bellomo; Luis Cam; Raul Llanos; Anne Castañeda; Lourdes Tucto; Theresa J Ochoa
Journal:  Biometals       Date:  2014-06-17       Impact factor: 2.949

10.  Effect of a new synbiotic supplement on symptoms, stool consistency, intestinal transit time and gut microbiota in patients with severe functional constipation: a pilot randomized double-blind, controlled trial.

Authors:  G Bazzocchi; T Giovannini; C Giussani; P Brigidi; S Turroni
Journal:  Tech Coloproctol       Date:  2014-08-05       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.